The Immune intelligence startup Serimmune, the company that delivers a holistic view of immunity to identify factors of a disease, has launched a new immune response mapping service for COVID-19. Serimmune wants to understand the relationship between antibody epitopes and parts of antigen molecules that bind to antibodies and the SARS-CoV-2 virus.
The company’s proprietary technology was originally developed at UC Santa Barbara.
The technology offers a new method to map the complete range of an individual’s antibodies with the help of a small blood sample. They do this through the use of a bacterial peptide display which is a screening mechanism that can separate the plasmid DNA from the antibody-bound bacteria in the sample. This DNA can then be sequenced to identify the epitopes, to further provide information about which antigens a patient was likely exposed to, as well as how their immune system responded to those antigens.
CEO of Serimmune Noah Nasser, who has attained a degree in molecular biology from UC San Diego and has worked for many diagnostics companies, remarked, “It is a highly multiplex and exquisite method of looking at the epitopes found by antibodies in a particular blood specimen.”
Serimmune a few days back announced the new application to help understand the immune responses to SARS-CoV-2 virus.
Noah Nasser explained the technique saying, “We use the antibody profiles we build, and then we can map those back with 12 amino acid specificity to SARS-CoV-2 proteome. The result we see is that the antibody expression is vastly correlated to the state of the disease. Thus it becomes easy to distinguish that if the disease is mild, moderate, or severe or asymptomatic on the basis of antibodies that are present in the given specimen.”
The more the patient data the company can collect, the better the core technology becomes at finding various medical patterns across different disease severity. Taking notes of these patterns and studies will help the physicians better understand how the SARS-CoV-2 virus operates? Moreover, researchers and physicians will also be able to inform new methods to diagnostics, treatments, and even vaccines for any antigens.
Serimmune’s launch of the new COVID-19 antibody epitope mapping service is a way to make this data widely accessible to its customers. The customers of Serimmune are the big vaccine companies, medical academic labs, and the government agencies or those showing interest in better understanding of the immune system’s response to SARS-CoV-2.